Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 10/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.65 |
| ▸ | ESR1 | P03372 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091039 | 0.95 | HTR3A (0.78) | HTR3AHSD17B10CACNA1GESR1KDM4E | |
| SCHEMBL13943783 | 0.87 | HTR3A (0.81) | HTR3AHSD17B10CACNA1GKDM4EALDH1A1 | |
| SCHEMBL13090998 | 0.87 | KMT2A (0.79) | HTR3ACACNA1GESR1KDM4EALDH1A1 | |
| SCHEMBL13091144 | 0.85 | ALDH1A1 (0.69) | HTR3AHSD17B10CACNA1GESR1KDM4E | |
| SCHEMBL13091052 | 0.83 | HTR3A (0.78) | HTR3AHSD17B10CACNA1GESR1KDM4E | |
| SCHEMBL13091071 | 0.83 | MAPT (0.73) | HTR3AHSD17B10CACNA1GESR1KDM4E | |
| SCHEMBL8227816 | 0.82 | HTR3A (1.00) | HTR3AHSD17B10CACNA1GKDM4EALDH1A1 | |
| SCHEMBL13091059 | 0.81 | ESR1 (0.62) | HTR3AHSD17B10CACNA1GESR1KDM4E | |
| SCHEMBL13091055 | 0.80 | ALDH1A1 (0.67) | HSD17B10ESR1KDM4EALDH1A1GAA | |
| SCHEMBL12793634 | 0.80 | ALDH1A1 (0.68) | HSD17B10ESR1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2009023558-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | BAX, BCL2, BAD | HTR3A 4236/4885HSD17B10 2550/4885CACNA1G 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.